Polaris Capital Management, an investment management company, released its third quarter 2024 investor letter. A copy of the ...

GILD has put up a steady performance in 2024, with a new drug approval, positive data readouts and strong quarterly results.

Gilead Sciences (GILD) and Terray Therapeutics have entered into a strategic collaboration to discover and develop small ...

Gilead Sciences Inc. closed $6.85 short of its 52-week high ($98.90), which the company achieved on November 11th.

Shares of Assembly Biosciences (NASDAQ:ASMB) traded higher on Thursday after Gilead Sciences (NASDAQ:GILD) agreed to increase ...

Investors are bullish on Gilead as the stock surges on successful launches and strong financial health, offering potential ...

About 40 customers of the Mt. Gilead-Improve Water Association in Columbia were put on a boil-water notice Sunday ...

Gilead Sciences will no longer provide four HIV medicines for free as part of a patient assistance program starting at the ...

Science magazine has chosen twice-yearly lenacapavir PrEP as its 2024 Breakthrough of the Year, recognizing it as a ...

Terray is ending the year on a high. Just two short months ago the biotech came out with a healthy $120 million series B ...

This was the stock's second consecutive day of gains.

Assembly Bio to receive approximately $20.1 million equity investment and $10 million in accelerated funding under the collaboration, extending ...